Amide substituted imidazoquinolines

Details Amide substituted imidazoquinolines Amide substituted imidazoquinolines

2004-05-19

2008-07-01

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S082000

Reexamination Certificate

active

07393859

ABSTRACT:
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

REFERENCES:
patent: 3314941 (1967-04-01), Littell et al.
patent: 3917624 (1975-11-01), Littell et al.
patent: 4689338 (1987-08-01), Gerster
patent: 4690930 (1987-09-01), Takada et al.
patent: 4698348 (1987-10-01), Gerster
patent: 4753951 (1988-06-01), Takada et al.
patent: 4775674 (1988-10-01), Meanwell et al.
patent: 4929624 (1990-05-01), Gerster et al.
patent: 4988815 (1991-01-01), Andre et al.
patent: 5037986 (1991-08-01), Gerster
patent: 5175296 (1992-12-01), Gerster
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster
patent: 5268376 (1993-12-01), Gerster
patent: 5346905 (1994-09-01), Gerster
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5367076 (1994-11-01), Gerster
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5395937 (1995-03-01), Nikolaides et al.
patent: 5444065 (1995-08-01), Nikolaides et al.
patent: 5446153 (1995-08-01), Lindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5494916 (1996-02-01), Lindstrom et al.
patent: 5525612 (1996-06-01), Gerster
patent: 5578727 (1996-11-01), Andre et al.
patent: 5585612 (1996-12-01), Harp, Jr.
patent: 5602256 (1997-02-01), Andre et al.
patent: 5605899 (1997-02-01), Gerster et al.
patent: 5627281 (1997-05-01), Nikolaides et al.
patent: 5644063 (1997-07-01), Lindstrom et al.
patent: 5648516 (1997-07-01), Nikolaides et al.
patent: 5693811 (1997-12-01), Lindstrom
patent: 5714608 (1998-02-01), Gerster
patent: 5741908 (1998-04-01), Gerster et al.
patent: 5741909 (1998-04-01), Gerster et al.
patent: 5756747 (1998-05-01), Gerster
patent: 5886006 (1999-03-01), Nikolaides et al.
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 5977366 (1999-11-01), Gerster et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6069149 (2000-05-01), Nanba et al.
patent: 6083505 (2000-07-01), Miller et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6323200 (2001-11-01), Gerster et al.
patent: 6331539 (2001-12-01), Crooks et al.
patent: 6348462 (2002-02-01), Gerster et al.
patent: 6365166 (2002-04-01), Beaurline et al.
patent: 6376669 (2002-04-01), Rice et al.
patent: 6451810 (2002-09-01), Coleman et al.
patent: 6486168 (2002-11-01), Skwierczynski et al.
patent: 6511485 (2003-01-01), Hirt et al.
patent: 6541485 (2003-04-01), Crooks et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6573273 (2003-06-01), Crooks et al.
patent: 6677349 (2004-01-01), Griesgraber
patent: 6756382 (2004-06-01), Coleman et al.
patent: 6780873 (2004-08-01), Crooks et al.
patent: 6784188 (2004-08-01), Crooks et al.
patent: 6894060 (2005-05-01), Slade
patent: 6897221 (2005-05-01), Crooks et al.
patent: 2002/0055517 (2002-05-01), Smith
patent: 2002/0058674 (2002-05-01), Hedenstrom et al.
patent: 2002/0110840 (2002-08-01), Tomai et al.
patent: 2004/0106638 (2004-06-01), Lindstrom
patent: 0394026 (1990-10-01), None
patent: 0894797 (1999-02-01), None
patent: 1104764 (2001-06-01), None
patent: 210 051 (1995-01-01), None
patent: 218 950 (2001-01-01), None
patent: 9-208584 (1997-08-01), None
patent: 9-255926 (1999-03-01), None
patent: 11-80156 (1999-03-01), None
patent: 11-222432 (1999-08-01), None
patent: 2000-247884 (2000-09-01), None
patent: WO 93/09119 (1993-05-01), None
patent: WO 95/02598 (1995-01-01), None
patent: WO 97/48704 (1997-12-01), None
patent: WO 98/30562 (1998-07-01), None
patent: WO 98/48805 (1998-11-01), None
patent: WO 99/29693 (1999-06-01), None
patent: WO 00/06577 (2000-02-01), None
patent: WO 00/09506 (2000-02-01), None
patent: WO 00/47719 (2000-08-01), None
patent: WO 00/76505 (2000-12-01), None
patent: WO 00/76518 (2000-12-01), None
patent: WO 01/74343 (2001-10-01), None
patent: WO 02/36592 (2002-05-01), None
patent: WO 02/46188 (2002-06-01), None
patent: WO 02/46189 (2002-06-01), None
patent: WO 02/46190 (2002-06-01), None
patent: WO 02/46191 (2002-06-01), None
patent: WO 02/46192 (2002-06-01), None
patent: WO 02/46193 (2002-06-01), None
patent: WO 02/46194 (2002-06-01), None
patent: WO 02/46749 (2002-06-01), None
patent: WO 02/102377 (2002-12-01), None
Miller, R.L. et. al., “Imiquimod applied topically: . . . ” International J. of Immunopharmacology, 1999, vol. 21, pp. 1-14.
Hart, E.P. “Napthyridines. Hydroxynaphthyridines”,Journal of Chemical Society, Part III, pp. 212-214, (1956).
Wozniak, et al, “The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate1,2. A New and Convenient Amination Method.”,Journal of the Royal Netherlands Chemical Society, 102, pp. 511-513, Dec. 12, 1983.
Brennan, et al, “Automated Bioassay of Interferons in Micro-test Plates”,Biotechniques, Jun./Jul., 78, 1983.
Testerman, et al, “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”,Journal of Leukocyte Biology, vol. 58, pp. 365-372, Sep. 1995.
Bachman, et al, “Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline”,J. Org. Chem, 15, pp. 1278-1284 (1950).
Jain, et al, “Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines”,J. Med. Chem., 11, pp. 87-92 (1968).
Baranov, et al.,Chem. Abs. 85, 94371, (1976).
Berényi, et al, “Ring Transformation of Condensed Dihydro-as-triazines”,J. Heterocyclic Chem., 18, pp. 1537-1540 (1981).
Bernstein et al., Daily or Weekly Therapy with Resiquimod (R-848) Reduces Genital Recurrences in Herpes Simplex Virus-Infected Guinea Pigs during and after Treatment,J of Infectious Diseases, vol. 183(6), pp. 844-849, 2001.
Diaz-Arrastia et al., “Clinical and Molecular Responses in High-Grade Intraepithelial Neoplasia Treated with Topical Imiquimod 5%”,Clinical Cancer Research, vol. 7(10), pp. 3031-3033, 2001.
Spruance et al., “Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot Study”,J of Infectious Diseases, vol. 184(2), pp. 196-200, 2001.
Brassard, et al, J. Leukocyte Biology, 71, 565-581 (2002).
Beutler, et al, Crit Care Med., 1993, 21, (10 Suppl), S423-S435.
Rothel, et al, Immunol Cell Biol., 1998 76(2), 167-72.
Wedlock, et al, Immunol Cell Biol., 1999, 77(1), 28-33.
Chollet, et al, Pharmaceutical Development and Technology, 4(1), pp. 35-43 (1999).
Belikov, V.G., Pharmaceutical Chemistry, M., Higher School, 1993, vol. 1, pp. 43-47.

Affiliated with

Also associated with

Rating

Amide substituted imidazoquinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amide substituted imidazoquinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amide substituted imidazoquinolines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3973695